UK Public Sector Contracts & Tenders

The NHS Genomic Medicine Service infrastructure, including the seven Genomic Laboratory Hubs (GLHs), enable the full repertoire of genomics testing for cancer patients in the NHS in England as outlined in the National Genomic Test Directory (Test Directory). Most of the somatic cancer testing in the Test Directory is based on testing the genetic make-up of an individual's tumour. This requires a tumour sample to be taken and then sent to the GLHs for testing. Increasingly it is becoming possible to use blood samples to test the circulating free DNA (cfDNA) for the presence of disease-causing mutations in circulating tumour DNA (ctDNA), also known as liquid biopsy testing. ctDNA based testing has now been validated, pan-cancer, in a number of different trials including I-SPY2, FLAUAS, AURA3, SCRUM-Japan, GOZILA, GRECO, MYSTIC, PEGASUS, COBRA, SOLAR1 and plasmaMATCH. ctDNA testing for EGFR gene mutations is already included on the Test Directory for lung cancer patients. To build the evidence base for the further roll out of ctDNA testing in the NHS, NHS England convened a group of experts to scope a project to explore ctDNA starting with suspected stage 3/4 non-small cell lung cancer patients. ctDNA samples will be taken from at least 700 patients with suspected thoracic malignancy without a confirmed histological diagnosis of stage 3/4 non-small cell lung cancer for direct gene panel analysis for those genes already approved on the Test Directory. ctDNA samples taken prior to the start of this project for patients with non-small cell lung cancer taken at the same time as tissue biopsy or after histological verification in parallel to tissue molecular analyses will also be included in this health economics evaluation. Numbers to be confirmed.

Added Value Portal t/a Pagabo, acting on behalf of Great Ormond Street Hospital for Children NHS Foundation Trust, is looking to establish a framework of Contractors who are capable of providing Decarbonisation Solutions. The framework will cover UK Public Health Sector and the NHS Trusts bodies only. The opportunity will consist of four value banded lots that cover Contractor delivery for a four-year term. The procurement will involve a single stage process following a Public Contract Regulations 2015 Open Procedure. This Framework Agreement is being advertised and tendered, so it can be utilised by all public health sector bodies in the UK, the full list of applicable public sector organisations is available in the Tender synopsis on Pagabo's In- Tend portal - https://in-tendhost.co.uk/pagabo/aspx/ProjectManage/1271 . The framework shall have the facility for Client Organisations to Direct Award and Further Compete their requirement

The Authority will be upgrading it’s BEMS (Building Energy Management System) over the next few years in phases. <br/>The Authority currently has a Trend 963 system, with outdated graphics, legacy controllers, and a lack of standardisation. We are taking this opportunity to upgrade our systems, including hardware and software, and to introduce wider improvements and improve site resilience. The current system has c125,000 points.

The Authority has a requirement for two tandem mass spectrometers for a new service to develop in-house pharmacokinetic (PK) / therapeutic drug monitoring (TDM) services. These should be triple quadrupole instruments each coupled to ultra-high performance liquid chromatography (UHPLC) hereinafter referred to as a “system”. Each system should include an autosampler, nitrogen generator, ion bench (or equivalent) to house each instrument, appropriate vacuum pumps, column manager and all necessary computer/VDU/ computer-related accessories. Systems do not necessarily have to be identical but each system must satisfy the specification.